secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2026-09-30T13:20:10+00:00
Accession:  0001193125-26-408435
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Q32 Bio reports positive SIGNAL-AA Part B bempikibart results in alopecia areata
--------------------------------------------------------------------------------

- Bempikibart achieved 35.3% mean SALT reduction at Week 36 in mITT; SALT-20 was 40.0% (10/25) mITT and 30.3% (10/33) ITT in severe/very severe alopecia areata.
- SALT 30 and SALT 50 responses each reached 44.0% (11/25) in mITT and 33.3% (11/33) in ITT at Week 36.
- In the 16-week off-drug period, 18 patients entered; SALT-20 was 44%, SALT 30 was 61%, SALT 50 was 50%; maintenance occurred in 100% of 12 Week 36 responders and deepening in 42%.
- Prior oral JAKi responders had 48.3% mean SALT reduction vs 4.8% for non-responders; JAK-naive patients had 44.1%.
- Safety: no serious or Grade 3+ treatment-related AEs; most common TEAE was injection site reaction at 36.3%, all mild; Q32 plans registration-directed AA program in H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526408435/0001193125-26-408435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526408435/d13352d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-408435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer